Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yigan Qingdu Granules
- Development stage
- Phase 2
- Lead developer
- Beijing Rongzhiyuan Pharmaceutical Technology
- Administration
- Oral
01
Overview
**Yigan Qingdu Granules** is an oral traditional Chinese medicine granule product developed by Beijing Rongzhiyuan Pharmaceutical Technology for chronic hepatitis B. It was evaluated in a randomized, double-blind, parallel-group, multicenter Phase II study as an adjunct to entecavir capsules, with the study assessing antiviral activity, improvement of traditional Chinese medicine syndrome features, and safety in patients with chronic hepatitis B. The product's individual botanical constituents, standardized active ingredients, and specific molecular targets have not been publicly established in the available trial information.
- Other names
- 益肝清毒颗粒
Beyond the preview
Go deeper on Yigan Qingdu Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yigan Qingdu Granules.